Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Background. The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with complicated urinary tract infection (cUTI), i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Infect Dis
Glavni autori: Wagenlehner, Florian M., Sobel, Jack D., Newell, Paul, Armstrong, Jon, Huang, Xiangning, Stone, Gregory G., Yates, Katrina, Gasink, Leanne B.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Articles and Commentaries
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4996135/
https://ncbi.nlm.nih.gov/pubmed/27313268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciw378
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items